The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

(RTTNews) - Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling certain Insulin Glargine (Insulin glargine-yfgn) Injection prefilled pens due to the potential for ...

The state’s CalRx Insulin Glargine will be available to consumers for a suggested retail price of $55 or less per five-pack of pens beginning Jan. 1, 2026. The insulin glargine pen agreement with ...

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell an affordable version of the drug to residents, Gov. Gavin Newsom announced ...

Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...

Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...

Please provide your email address to receive an email when new articles are posted on . Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection ...